December 30, 2020
The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine. The vaccine also demonstrated efficacy in preventing severe COVID-19. Investigators identified no safety concerns and no evidence of vaccine-associated enhanced respiratory disease (VAERD). Read more
Reading level: Grade 12
EurekAlert!, the online, global news service operated by AAAS, the science society
Please Give Us Feedback!

Why are you reading this article? (check all that apply)







How do you feel about science?







Send Feedback
Free science fair projects.